These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31784406)

  • 1. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations.
    Zalcberg I; D'Andrea MG; Monteiro L; Pimenta G; Xisto B
    Hematol Transfus Cell Ther; 2020; 42(3):269-274. PubMed ID: 31784406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
    Malcikova J; Tausch E; Rossi D; Sutton LA; Soussi T; Zenz T; Kater AP; Niemann CU; Gonzalez D; Davi F; Gonzalez Diaz M; Moreno C; Gaidano G; Stamatopoulos K; Rosenquist R; Stilgenbauer S; Ghia P; Pospisilova S;
    Leukemia; 2018 May; 32(5):1070-1080. PubMed ID: 29467486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Bazinet A; Rys RN; Barry A; Greenwood CMT; Young YK; Mendoza A; LaPorta I; Wever CM; Mercier FE; Johnson NA
    Leuk Lymphoma; 2021 Oct; 62(10):2352-2359. PubMed ID: 34020575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
    Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
    Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Medicine Management of Chronic Lymphocytic Leukemia.
    Moia R; Patriarca A; Schipani M; Ferri V; Favini C; Sagiraju S; Al Essa W; Gaidano G
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
    Malcikova J; Pavlova S; Baliakas P; Chatzikonstantinou T; Tausch E; Catherwood M; Rossi D; Soussi T; Tichy B; Kater AP; Niemann CU; Davi F; Gaidano G; Stilgenbauer S; Rosenquist R; Stamatopoulos K; Ghia P; Pospisilova S
    Leukemia; 2024 Jul; 38(7):1455-1468. PubMed ID: 38755420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.
    Farren TW; Sadanand KS; Agrawal SG
    Front Oncol; 2020; 10():597730. PubMed ID: 33344247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
    Fontecha MB; Anadón MDR; Mercado Guzmán V; Stanganelli C; Galvano C; Tosin F; Bordone J; Bezares R; Rodríguez C; Heller V; Slavutsky I; Fundia AF
    Ann Hematol; 2024 May; ():. PubMed ID: 38743086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
    Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
    Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
    Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision diagnostics in chronic lymphocytic leukemia: Past, present and future.
    Mollstedt J; Mansouri L; Rosenquist R
    Front Oncol; 2023; 13():1146486. PubMed ID: 37035166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic lymphocytic leukemia: update on pathophysiology and management].
    Suzumiya J
    Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.
    Yun X; Zhang Y; Wang X
    Biomark Res; 2020; 8():40. PubMed ID: 32939265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.